Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.

Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Cecchi F, Chrostowska M, De la Sierra A, Domenech M, Dorobantu M, Faria T, Huo Y, Jelaković B, Kahan T, Konradi A, Laurent S, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Octavio JA, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Renna N, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Veglio F, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, Zhang Y.

BMJ Open. 2018 Dec 19;8(12):e021038. doi: 10.1136/bmjopen-2017-021038.

2.

Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP).

Parasole R, Valsecchi MG, Silvestri D, Locatelli F, Barisone E, Petruzziello F, Putti MC, Micalizzi C, Colombini A, Mura R, Mina T, Testi AM, Notarangelo LD, Santoro N, Casini T, Consarino C, Nigro LL, Ziino O, Giagnuolo G, Rizzari C, Conter V.

Blood Cancer J. 2018 Nov 15;8(12):115. doi: 10.1038/s41408-018-0150-z. No abstract available.

3.

Graphical representations and summary indicators to assess the performance of risk predictors.

Antolini L, Tassistro E, Valsecchi MG, Bernasconi DP.

Biom J. 2018 Oct 5. doi: 10.1002/bimj.201700186. [Epub ahead of print]

PMID:
30290002
4.

ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells.

Portale F, Cricrì G, Bresolin S, Lupi M, Gaspari S, Silvestri D, Russo B, Marino N, Ubezio P, Pagni F, Vergani P, Te Kronnie G, Valsecchi MG, Locatelli F, Rizzari C, Biondi A, Dander E, D'Amico G.

Haematologica. 2018 Sep 27. pii: haematol.2018.188664. doi: 10.3324/haematol.2018.188664. [Epub ahead of print]

5.

Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.

Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso ÁM, Mora J, Locatelli F, Bertaina A, Padilla L, Rodríguez-Manzaneque JC, Bueno C, Menéndez P.

Leukemia. 2018 Oct;32(10):2306. doi: 10.1038/s41375-018-0236-4.

PMID:
30218009
6.

Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor.

Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M.

Haematologica. 2019 Jan;104(1):e13-e16. doi: 10.3324/haematol.2018.199422. Epub 2018 Sep 13. No abstract available.

7.

Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study.

Talvik A, Rebora P, Heinpalu-Kuum M, Salerno S, Miszkowska-Nagórna E, Liu X, Comotti T, Świerblewska E, Valsecchi MG, Fadl Elmula FEM, Larstorp AC, Narkiewicz K, Parati G, Laurent S, Viigimaa M; BEtter control of blood pressure in hypertensive pAtients monitored Using the hoTman® sYstem (BEAUTY) Study Investigators.

Blood Press. 2018 Dec;27(6):368-375. doi: 10.1080/08037051.2018.1505425. Epub 2018 Aug 21.

PMID:
30129785
8.

Effects of antenatal indomethacin on ductus arteriosus early closure and on adverse outcomes in preterm neonates.

Doni D, Paterlini G, Locatelli A, Arnoldi S, Magri MC, Bernasconi D, Valsecchi MG, Tagliabue PE.

J Matern Fetal Neonatal Med. 2018 Aug 13:1-6. doi: 10.1080/14767058.2018.1499091. [Epub ahead of print]

PMID:
29986620
9.

Effects of Lifestyle Modifications on Elevated Blood Pressure and Excess Weight in a Population of Italian Children and Adolescents.

Genovesi S, Orlando A, Rebora P, Giussani M, Antolini L, Nava E, Parati G, Valsecchi MG.

Am J Hypertens. 2018 Sep 11;31(10):1147-1155. doi: 10.1093/ajh/hpy096.

PMID:
29982339
10.

Long-term survivors of childhood cancer: cure and care-the Erice Statement (2006) revised after 10 years (2016).

Jankovic M, Haupt R, Spinetta JJ, Beck JD, Byrne J, Calaminus G, Lackner H, Biondi A, Oeffinger K, Hudson M, Skinner R, Reaman G, van der Pal H, Kremer L, den Hartogh J, Michel G, Frey E, Bardi E, Hawkins M, Rizvi K, Terenziani M, Valsecchi MG, Bode G, Jenney M, de Vathaire F, Garwicz S, Levitt GA, Grabow D, Kuehni CE, Schrappe M, Hjorth L; participants in PanCare.

J Cancer Surviv. 2018 Oct;12(5):647-650. doi: 10.1007/s11764-018-0701-0. Epub 2018 Jun 26.

PMID:
29946794
11.

The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.

Paganin M, Grillo MF, Silvestri D, Scapinello G, Buldini B, Cazzaniga G, Biondi A, Valsecchi MG, Conter V, Te Kronnie G, Basso G.

Br J Haematol. 2018 Sep;182(5):705-711. doi: 10.1111/bjh.15449. Epub 2018 Jun 25.

PMID:
29938780
12.

Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: the need to present minimal important differences units in meta-analyses.

Gianola S, Andreano A, Castellini G, Moja L, Valsecchi MG.

Health Qual Life Outcomes. 2018 May 15;16(1):91. doi: 10.1186/s12955-018-0924-9.

13.

Cancer of the head and neck: a set of indicators based on register and administrative data.

Andreano A, Ansarin M, Alterio D, Bruschini R, Valsecchi MG, Russo AG.

Acta Otorhinolaryngol Ital. 2018 Feb;38(1):13-23. doi: 10.14639/0392-100X-1934.

14.

The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.

Andreano A, Peake MD, Janes SM, Valsecchi MG, Pritchard-Jones K, Hoag JR, Gross CP.

J Thorac Oncol. 2018 Jul;13(7):904-914. doi: 10.1016/j.jtho.2018.04.022. Epub 2018 May 1.

PMID:
29727739
15.

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.

Alberti P, Rossi E, Argyriou AA, Kalofonos HP, Briani C, Cacciavillani M, Campagnolo M, Bruna J, Velasco R, Cazzaniga ME, Cortinovis D, Valsecchi MG, Cavaletti G.

Support Care Cancer. 2018 Sep;26(9):3143-3151. doi: 10.1007/s00520-018-4170-9. Epub 2018 Mar 29.

PMID:
29594485
16.

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group.

J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.

PMID:
29498923
17.

Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.

Parini R, De Lorenzo P, Dardis A, Burlina A, Cassio A, Cavarzere P, Concolino D, Della Casa R, Deodato F, Donati MA, Fiumara A, Gasperini S, Menni F, Pagliardini V, Sacchini M, Spada M, Taurisano R, Valsecchi MG, Di Rocco M, Bembi B.

Orphanet J Rare Dis. 2018 Feb 8;13(1):32. doi: 10.1186/s13023-018-0771-0.

18.

Assessing the effect of a partly unobserved, exogenous, binary time-dependent covariate on survival probabilities using generalised pseudo-values.

Pötschger U, Heinzl H, Valsecchi MG, Mittlböck M.

BMC Med Res Methodol. 2018 Jan 19;18(1):14. doi: 10.1186/s12874-017-0430-5.

19.

Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis: A Randomized Clinical Trial.

Zamboni P, Tesio L, Galimberti S, Massacesi L, Salvi F, D'Alessandro R, Cenni P, Galeotti R, Papini D, D'Amico R, Simi S, Valsecchi MG, Filippini G; Brave Dreams Research Group.

JAMA Neurol. 2018 Jan 1;75(1):35-43. doi: 10.1001/jamaneurol.2017.3825.

20.

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, Cario G, Rizzari C, Attarbaschi A, Valsecchi MG, Bartram CR, Barisone E, Niggli F, Niemeyer C, Testi AM, Mann G, Ziino O, Schäfer B, Panzer-Grümayer R, Beier R, Parasole R, Göhring G, Ludwig WD, Casale F, Schlegel PG, Basso G, Conter V.

J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.

21.

Clinical states of cirrhosis and competing risks.

D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG.

J Hepatol. 2018 Mar;68(3):563-576. doi: 10.1016/j.jhep.2017.10.020. Epub 2017 Oct 27. Review.

PMID:
29111320
22.

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A.

Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.

23.

NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.

Prieto C, López-Millán B, Roca-Ho H, Stam RW, Romero-Moya D, Rodríguez-Baena FJ, Sanjuan-Pla A, Ayllón V, Ramírez M, Bardini M, De Lorenzo P, Valsecchi MG, Stanulla M, Iglesias M, Ballerini P, Carcaboso ÁM, Mora J, Locatelli F, Bertaina A, Padilla L, Carlos Rodríguez-Manzaneque J, Bueno C, Menéndez P.

Leukemia. 2018 Mar;32(3):633-644. doi: 10.1038/leu.2017.294. Epub 2017 Sep 25. Erratum in: Leukemia. 2018 Oct;32(10):2306.

24.

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.

Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, Micalizzi C, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M.

Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22. No abstract available.

25.

Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI.

Ferla R, Alliegro M, Marteau JB, Dell'Anno M, Nusco E, Pouillot S, Galimberti S, Valsecchi MG, Zuliani V, Auricchio A.

Mol Ther Methods Clin Dev. 2017 Jul 24;6:143-158. doi: 10.1016/j.omtm.2017.07.004. eCollection 2017 Sep 15.

26.

Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I.

Azario I, Pievani A, Del Priore F, Antolini L, Santi L, Corsi A, Cardinale L, Sawamoto K, Kubaski F, Gentner B, Bernardo ME, Valsecchi MG, Riminucci M, Tomatsu S, Aiuti A, Biondi A, Serafini M.

Sci Rep. 2017 Aug 25;7(1):9473. doi: 10.1038/s41598-017-09958-9.

27.

New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.

D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG.

Hepatol Int. 2018 Feb;12(Suppl 1):34-43. doi: 10.1007/s12072-017-9808-z. Epub 2017 Jul 5. Review.

PMID:
28681347
28.

Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).

Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK; CI-PeriNomS Group.

Qual Life Res. 2017 Nov;26(11):2999-3010. doi: 10.1007/s11136-017-1626-1. Epub 2017 Jun 20.

PMID:
28634676
29.

Preoperative Oral Carbohydrate Load Versus Placebo in Major Elective Abdominal Surgery (PROCY): A Randomized, Placebo-controlled, Multicenter, Phase III Trial.

Gianotti L, Biffi R, Sandini M, Marrelli D, Vignali A, Caccialanza R, Viganò J, Sabbatini A, Di Mare G, Alessiani M, Antomarchi F, Valsecchi MG, Bernasconi DP.

Ann Surg. 2018 Apr;267(4):623-630. doi: 10.1097/SLA.0000000000002325.

PMID:
28582271
30.

Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.

Cazzaniga G, Bisanti L, Randi G, Deandrea S, Bungaro S, Pregliasco F, Perotti D, Spreafico F, Masera G, Valsecchi MG, Biondi A, Greaves M.

Leukemia. 2017 Aug;31(8):1819-1821. doi: 10.1038/leu.2017.127. Epub 2017 Apr 27. No abstract available.

31.

High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia.

Vendramini E, Giordan M, Giarin E, Michielotto B, Fazio G, Cazzaniga G, Biondi A, Silvestri D, Valsecchi MG, Muckenthaler MU, Kulozik AE, Gattei V, Izraeli S, Basso G, Te Kronnie G.

Oncotarget. 2017 Jun 27;8(26):42398-42413. doi: 10.18632/oncotarget.16392.

32.

Adherence to guidelines and breast cancer patients survival: a population-based cohort study analyzed with a causal inference approach.

Andreano A, Rebora P, Valsecchi MG, Russo AG.

Breast Cancer Res Treat. 2017 Jul;164(1):119-131. doi: 10.1007/s10549-017-4210-z. Epub 2017 Apr 1.

PMID:
28365831
33.

Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.

Dander E, De Lorenzo P, Bottazzi B, Quarello P, Vinci P, Balduzzi A, Masciocchi F, Bonanomi S, Cappuzzello C, Prunotto G, Pavan F, Pasqualini F, Sironi M, Cuccovillo I, Leone R, Salvatori G, Parma M, Terruzzi E, Pagni F, Locatelli F, Mantovani A, Fagioli F, Biondi A, Garlanda C, Valsecchi MG, Rovelli A, D'Amico G.

Oncotarget. 2016 Dec 13;7(50):82123-82138. doi: 10.18632/oncotarget.13488.

34.

Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study.

Genovesi S, Rebora P, Gallieni M, Stella A, Badiali F, Conte F, Pasquali S, Bertoli S, Ondei P, Bonforte G, Pozzi C, Rossi E, Valsecchi MG, Santoro A.

J Nephrol. 2017 Aug;30(4):573-581. doi: 10.1007/s40620-016-0364-8. Epub 2016 Nov 11.

PMID:
27834042
35.

[The contribution of the Italian Association of paediatric haematology and oncology (AIEOP)].

Rondelli R, Jankovic M, Soresina A, Valsecchi MG, De Rosa M, Cuttini M, Haupt R, Aricò M, Bisogno G, Locatelli F, Magnani C, Merletti F, Zecca M, Pession A.

Epidemiol Prev. 2016 Sep-Oct;40(5Suppl2):23-27. Italian.

36.

Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.

Trentin L, Bresolin S, Giarin E, Bardini M, Serafin V, Accordi B, Fais F, Tenca C, De Lorenzo P, Valsecchi MG, Cazzaniga G, Kronnie GT, Basso G.

Sci Rep. 2016 Oct 4;6:34449. doi: 10.1038/srep34449.

37.

The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.

Antillón FG, Blanco JG, Valverde PD, Castellanos M, Garrido CP, Girón V, Letona TR, Osorio EJ, Borrayo DA, Mack RA, Melgar MA, Lorenzana R, Ribeiro RC, Metzger M, Conter V, Rossi E, Valsecchi MG.

Cancer. 2017 Feb 1;123(3):436-448. doi: 10.1002/cncr.30257. Epub 2016 Sep 28.

38.

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment.

Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, Ladisa N, Sighinolfi L, Dal Zoppo S, Sabbatini F, Soria A, Pezzoli C, Mondi A, Costarelli S, Valsecchi MG, Torti C, Gori A; Italian MASTER cohort.

PLoS One. 2016 Sep 15;11(9):e0162320. doi: 10.1371/journal.pone.0162320. eCollection 2016.

39.

Clinical and socio-demographic determinants of self-care behaviours in patients with heart failure and diabetes mellitus: A multicentre cross-sectional study.

Ausili D, Rebora P, Di Mauro S, Riegel B, Valsecchi MG, Paturzo M, Alvaro R, Vellone E.

Int J Nurs Stud. 2016 Nov;63:18-27. doi: 10.1016/j.ijnurstu.2016.08.006. Epub 2016 Aug 16.

PMID:
27567403
40.

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.

Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Della Mina P, Nagel S, Barisone E, Casale F, Locatelli F, Lo Nigro L, Micalizzi C, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Te Kronnie G, Cazzaniga G.

Oncotarget. 2016 Sep 13;7(37):59260-59272. doi: 10.18632/oncotarget.10610.

41.

Impact of Continuous vs Bolus Feeding on Splanchnic Perfusion in Very Low Birth Weight Infants: A Randomized Trial.

Bozzetti V, Paterlini G, De Lorenzo P, Gazzolo D, Valsecchi MG, Tagliabue PE.

J Pediatr. 2016 Sep;176:86-92.e2. doi: 10.1016/j.jpeds.2016.05.031. Epub 2016 Jun 20.

PMID:
27339251
42.

Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk.

Viazzi F, Rebora P, Giussani M, Orlando A, Stella A, Antolini L, Valsecchi MG, Pontremoli R, Genovesi S.

Hypertension. 2016 May;67(5):934-40. doi: 10.1161/HYPERTENSIONAHA.115.06852. Epub 2016 Mar 28.

PMID:
27021006
43.

Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia.

Driessen EM, Pinhanços SS, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW.

Eur J Cancer. 2016 Apr;57:87-90. doi: 10.1016/j.ejca.2015.12.031. Epub 2016 Feb 19. No abstract available.

PMID:
26901613
44.

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M.

Blood. 2016 Apr 28;127(17):2101-12. doi: 10.1182/blood-2015-09-670729. Epub 2016 Feb 17.

45.

Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE-related hemochromatosis.

Pelucchi S, Galimberti S, Greni F, Rametta R, Mariani R, Pelloni I, Girelli D, Busti F, Ravasi G, Valsecchi MG, Valenti L, Piperno A.

J Gastroenterol Hepatol. 2016 Jul;31(7):1342-8. doi: 10.1111/jgh.13315.

PMID:
26868056
46.

Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.

Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P, Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G.

Lancet Haematol. 2016 Feb;3(2):e80-6. doi: 10.1016/S2352-3026(15)00254-9. Epub 2016 Jan 26.

PMID:
26853647
47.

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.

Vora A, Andreano A, Pui CH, Hunger SP, Schrappe M, Moericke A, Biondi A, Escherich G, Silverman LB, Goulden N, Taskinen M, Pieters R, Horibe K, Devidas M, Locatelli F, Valsecchi MG.

J Clin Oncol. 2016 Mar 20;34(9):919-26. doi: 10.1200/JCO.2015.64.2850. Epub 2016 Jan 11.

48.

Crude incidence in two-phase designs in the presence of competing risks.

Rebora P, Antolini L, Glidden DV, Valsecchi MG.

BMC Med Res Methodol. 2016 Jan 11;16:5. doi: 10.1186/s12874-015-0103-1.

49.

Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities.

van der Linden MH, Boer JM, Schneider P, Willekes M, Seslija L, De Lorenzo P, Valsecchi MG, Cazzaniga G, Biondi A, den Boer ML, Pieters R, Stam RW.

Haematologica. 2016 Mar;101(3):e95-8. doi: 10.3324/haematol.2014.122119. Epub 2015 Dec 17. No abstract available.

50.

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Franca R, Rebora P, Bertorello N, Fagioli F, Conter V, Biondi A, Colombini A, Micalizzi C, Zecca M, Parasole R, Petruzziello F, Basso G, Putti MC, Locatelli F, d'Adamo P, Valsecchi MG, Decorti G, Rabusin M.

Pharmacogenomics J. 2017 Jan;17(1):4-10. doi: 10.1038/tpj.2015.83. Epub 2015 Dec 8.

PMID:
26644204

Supplemental Content

Loading ...
Support Center